By Chris Wack
LivaNova shares were trading 9% higher, at $60.52, after the company said the U.S. Centers for Medicare & Medicaid Services assigned VNS Therapy to New Technology Ambulatory Payment Classification 1580 for new patient implants under the 2026 Medicare Hospital Outpatient Prospective Payment System.
The stock hit its 52-week high of $61.48 earlier in the session, and is up 18% in the past 12 months.
VNS Therapy is a LivaNova neuromodulation treatment for patients 4 years of age and older with drug-resistant epilepsy and focal seizures.
The medical technology company said CMS also moved VNS Therapy end-of-service procedures from Level 4 into the Level 5 APC.
LivaNova said that effective Jan. 1, 2026, provider reimbursement for VNS Therapy DRE procedures under Medicare will increase significantly. The changes also significantly reduce a known barrier to procedure penetration as current hospital reimbursement rates for Medicare patients often don't fully cover procedure costs.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
November 24, 2025 10:47 ET (15:47 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.